Fig. 1From: Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA reviewForest plot of key endpoints in Study 301 and Study 302 with GSTs combining endpoints within the studies and between studies. The assumed correlation between endpoints within studies was 0.3, while correlation between studies was assumed to be 0 due to the independent populationsBack to article page